CN-21 RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825

BACKGROUND: TMZ is well tolerated with a relatively low incidence of myelotoxicity, which can nonetheless result in treatment delays or death. Our goal was to evaluate risk and validate prediction models in newly diagnosed patients treated with TMZ +/- bevacizumab (BEV). METHODS: Models (from recurr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Zhou, Renke, Scheurer, Michael, Vera-Bolanos, Elizabeth, Gilbert, Mark, Bondy, Melissa, Sulman, Eric, Hilsenbeck, Sue, Wendland, Merideth, Brachman, David, Roof, Kevin, Komaki, Ritsuko, Deutsch, Melvin, Andrews, David, Anderson, Bethany, Lee, R. Jeffrey, Pugh, Stephanie, Armstrong, Terri
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218016/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou243.21
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares